Health Care
featured
The American Medical Association says obesity should be classified as a disease. CNBC's Bertha Coombs reports AMA's Patrice Harris says the hope is for doctors to be more proactive in treating obese patients.
» Read More
More
-
Shares of Sarepta Therapeutics Inc. jumped Wednesday, after the drug developer said its lead candidate, a potential treatment for Duchenne muscular dystrophy, continued to help patients in an extended mid-stage trial.
-
BRUSSELS, June 19- European antitrust regulators fined nine drugmakers, including Denmark's Lundbeck, a total of 146 million euros for blocking the supply of a cheaper anti-depressant to the market, the first EU sanction against such deals.
-
BRUSSELS, June 19- Nine drugmakers, including Denmark's Lundbeck, were fined a total of 146 million euros by EU antitrust regulators on Wednesday for blocking the supply of a cheaper anti-depressant medicine to the market.
-
BRUSSELS, June 19- EU antitrust regulators fined nine drugmakers a total of 146 million euros on Wednesday for blocking the supply of cheaper medicines on the market, with a penalty of 94 million euros imposed on Denmark's Lundbeck.
-
TAKEOVER UPDATE: Royalty Pharma said Tuesday it has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.
-
With the Dow up more than 2000 points for the year, Jim Cramer thinks now is a good time to single out stocks that haven’t rallied, but soon could.
-
Shares of Medtronic Inc. slipped Tuesday, a day after the medical device maker announced findings from independent reviews of studies of its Infuse bone graft.
-
NEW YORK-- Shares of drug developer Synergy Pharmaceuticals Inc. traded higher Monday after a Citi Investment Research analyst started covering the stock with a "Buy" rating based on the company's constipation drug candidate plecanatide. THE BIG PICTURE: The New York company has no approved drugs, and plecanatide is its most advanced experimental product.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday regulators can challenge deals between brand-name drug companies and generic rivals that delay cheaper medicines from going on sale, which regulators say increase costs to consumers by billions of dollars.
-
NEW YORK-- BioScrip Inc. plans to expand its drug infusion business with a $223 million acquisition of CarePoint, which administers drugs to patients in their homes and other locations outside of hospitals. BioScrip expects about $160 million in annual revenue from CarePoint, while BioScrip posted $663 million in revenue in 2012..
-
NEW YORK, June 17- ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
-
A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.
-
NEW YORK, June 17- ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.
-
The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals brand-name drug companies make with generic rivals that keep cheaper products off the market.
-
SOUTH SAN FRANCISCO, Calif.-- Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through. South San Francisco, Calif.- based Theravance said Monday it will split into businesses named Royalty Management Co. and Theravance Biopharma.
-
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
-
DUBLIN/ NEW YORK, June 14- Irish drug company Elan put itself up for sale on Friday, seeking to fend off a hostile bid by Royalty Pharma that shareholders will consider next week. "Elan Corporation... today announced that it is proceeding with a formal sale process in light of the expressions of interest received to date," the company said in a statement.
-
Dawn Zier, President & CEO of Nutrisystem, discusses her company's plans to set up programs designed to meet the needs of people with special dietary needs, and its expansion into selling its products in Wal-Mart.
-
June 13- The U.S. Food and Drug Administration on Thursday urged medical device makers and medical facilities to upgrade security protections to protect against potential cyber threats that could compromise the devices or patient privacy.
Most Popular Video
No reason has been given yet for the departure of founder and executive chairman George Zimmer, reports CNBC's Courtney Reagan. Zimmer has long been the face of the company.
Wednesday, 19 Jun 2013 | 10:52 AM ETCNBC's Rick Santelli, explains why he hears 'crickets" when he asks questions about Fed Chairman Bernanke's policies. "Enough is enough," he rants.
Wednesday, 19 Jun 2013 | 11:36 AM ETAre reporters lobbing "softball" questions at the Fed chairman? CNBC's Rick Santelli and the Wall Street Journal's Jon Hilsenrath, debate whether the economy continues to need quantitative easing. I'm trying to inform the public about what the Fed is up to, says Hilsenrath.